Bayer's Courtroom Clock and Cash Burn Test the Bull Case

Bayer shares drew two very different kinds of good news this week, and the market's reaction says as much about what remains unresolved as about what has been fixed. A Chinese approval for a lung-cancer drug and a stronger-than-expected third quarter both landed, yet the stock's advance still runs through a Missouri courtroom and a balance sheet that continues to leak cash.

The legal calendar is the first thing investors cannot ignore. CEO Bill Anderson said on Tuesday that Bayer expects a ruling before Christmas on its proposed $7.25 billion settlement of the glyphosate litigation, a package still under review by a court in Missouri. An expected decision is not an approval, and a proposed deal is not a completed clean-up. The pre-Christmas timing gives shareholders a marker to watch; it does nothing to remove the uncertainty hanging over the outcome.

That caution is reinforced by a genuinely encouraging courtroom result. On October 30, a St. Louis jury voted unanimously in Monsanto's favor, dismissing claims brought by three women in the glyphosate proceedings. A second account places the verdict on October 29, when all jurors in the first glyphosate trial since the US Supreme Court's ruling sided with Monsanto, with the company arguing plaintiffs could not prove their claims. Either way, the win argues against viewing Bayer's legal exposure purely through the lens of potential liabilities. It would be just as wrong to read a single trial victory as an all-clear. The jury result and the settlement review are separate matters and should be kept apart when sizing up the equity.

The operating story carries more weight

Harder evidence for optimism comes from the numbers. Bayer reported third-quarter 2026 EBITDA before special items of EUR 1.615 billion, up 6.9%, with the pharmaceutical business driving the improvement. Revenue for the quarter came in at EUR 10.053 billion. That is reported performance rather than hope pinned on a judge's ruling, which is why it is the more persuasive force behind the share-price move.

Should investors sell immediately? Or is it worth buying Bayer?

The profit line tells a more mixed story. Bayer posted a net loss of EUR 672 million, narrower than the EUR 963 million recorded a year earlier. The loss shrank; it did not disappear. Investors leaning optimistic should look past the adjusted figure rather than treat the group as already consistently profitable.

Guidance got a lift on Tuesday as well. Bayer raised its forecast for the pharma margin before special items to 25% to 27% and trimmed its expectation for net financial debt to EUR 28 billion to EUR 29 billion. For the full 2026 financial year, the company now expects EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion, citing the strength of the pharma division. These remain forecasts — a description of what Bayer expects, not solely of what it has already delivered — and that distinction should shape how the stock is valued.

China adds a second front

The regulatory news broadens the pharma picture. Bayer announced Chinese first-line approval for Sevabertinib in adults with advanced HER2-mutant non-small cell lung cancer, based on data from the ongoing Phase I/II SOHO-01 study. This is a regulatory decision in hand, not a pending review. It creates the conditions for treating patients in the approved indication, though it does not by itself prove any particular revenue contribution.

Sevabertinib is not alone. Asundexian won Chinese approval on October 26 for reducing the risk of stroke in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Two approvals in different therapeutic areas offer the chance that several pharma advances could contribute to growth — a sturdier investment case than betting on a single compound. Concrete earnings contributions cannot be inferred from the approvals alone.

Cash flow is the counterweight

The strongest argument against the bull case is financial rather than scientific. Bayer expects free cash flow of minus EUR 1.5 billion to minus EUR 0.5 billion for the current financial year, so even the improved guidance still points to an outflow. A higher operating result and additional approvals do not automatically solve that. The quality of the improvement matters: a stronger profit would be more convincing if it showed up in liquidity. Otherwise the financial position could cap the valuation despite the medical progress.

Bayer at a turning point? This analysis reveals what investors need to know now.

The analyst community reflects that tension. Deutsche Bank Research reaffirmed its buy rating with a EUR 60 target yesterday, while Jefferies stuck with a hold and a EUR 46 target on Tuesday. Media reports said UBS and Goldman Sachs each raised their targets to EUR 66 yesterday. Those targets are opinions, not guaranteed prices — and the spread from 46 to 66 euros captures the split between those betting on the pharma engine and those waiting for proof.

A further scientific catalyst is scheduled: new data on cardiovascular disease, kidney disease and stroke, which Bayer plans to present at the American Heart Association's 2026 scientific sessions. Such data can sharpen the medical outlook but cannot substitute for evidence of commercial returns.

Weighed together, the re-rating is understandable on operating grounds and not yet sufficiently underpinned on legal ones. Pharma strength is durable progress; whether it becomes a broadly secured recovery also depends on how the court rules on the proposed settlement. Until then, reasoned optimism is more appropriate than an all-clear.

Ad

Bayer Stock: New Analysis - 5 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...